Anti-Mouse CD366 (Tim-3) – Biotin

This antibody was produced using recombinant mouse TIM-3

This biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.

Next Day 2-8°C

Blue Laser (488 nm) and/or Green Laser (532 nm)/Yellow-Green Laser (561 nm)

B
IHC

Clone RMT2-23 recognizes an epitope on mouse Tim-3.

Tim-3 antibody, clone RMT3-23, recognizes T cell immunoglobulin and mucin domain-containing protein 3 (TIM3, also known as CD366), a TIM family member of immunoregulatory proteins. Tim-3 is a 60kDa type I transmembrane protein with an extracellular immunoglobulin and mucin-like domain and a cytoplasmic tyrosine phosphorylation motif. Tim-3 is expressed by IFNg-producing Th1 CD4 and Tc1 (cytotoxic) CD8 T cells¹, regulatory T cells (Tregs)², myeloid cells³, NK cells⁴, and mast cells⁵. Tim-3 is an inhibitory molecule that limits Th1-mediated inflammatory diseases, including a model of central nervous system inflammation (experimental autoimmune encephalomyelitis, EAE)¹, inflammatory bowel disease (IBD)⁶, and type I diabetes⁷. Tim-3 is also proposed to induce immunological tolerance⁷, promote Th1 apoptosis⁸, and regulate macrophage activation1. In addition, Tim-3 is upregulated on tumor-infiltrating lymphocytes, and coblockade of Tim-3 and immune checkpoint inhibitors, such as PD-1, is currently being investigated in clinical trials for the treatment of cancer⁹.

Tim-3 is expressed on activated Th1 and Tc1 lymphocytes, CD11b+ macrophages, Tregs, NK cells, and mast cells.

Putative ligand on resting CD4+ lymphocytes

May play a role in the development of immune responses and the development of Th1-mediated responses

1. Monney, L. et al. (2002)Nature 415, 536–541.
2. Gao, X. et al. (2012) PLOS ONE 7, e30676.
3. Anderson, A. C. et al. (2007) Science 318, 1141–1143.
4. Ndhlovu, L. C. et al. (2012) Blood 119, 3734–3743.
5. Phong, B. L. et al. J. (2015) Exp. Med. 212, 2289–2304.
6. Li, X. et al. (2010) Clin. Immunol. 134, 169–177.
7. Sanchez-Fueyo, A. et al. (2003) Nat. Immunol. 4, 1093–1101.
8. Zhu C, et al.. Nature Immunology. 2005;6:1245–1252.